FAKTOR-OPTIONSSCHEIN - ELI LILLY & CO | Real-time Boerse Frankfurt Warrants 04:58:24 2024-07-11 am EDT | ||
| 679.6 EUR | +2.87% |
|
| Current month | +28.44% | ||
| 1 month | +92.02% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-07-11 | 679.6 | +2.87% |
| 24-07-10 | 660.6 | +5.81% |
| 24-07-09 | 624.4 | +20.13% |
| 24-07-08 | 519.7 | +0.84% |
| 24-07-05 | 515.4 | +19.01% |
Real-time Boerse Frankfurt Warrants
Last update July 11, 2024 at 04:58 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SD42EB |
| ISIN | DE000SD42EB3 |
| Date issued | 2021-03-29 |
| Strike | 183.1 $ |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 8.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 690 € |
|---|---|
| Lowest since issue | 1.76 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
939.8
USD
Average target price
874.8
USD
Spread / Average Target
-6.92%
- Stock Market
- Certificates
- Certificat
